August 21st 2025
Patients with higher exposure to nature and green spaces were significantly less likely to experience dry eye, investigators reported
Phase II corneal health clinical program initiated for pharmaceutical platform
March 16th 2022Glaukos Corp’s iLink therapy for the treatment of keratoconus consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilise and reshape the cornea.
A simple solution for complex corneas
February 7th 2022Corneal aberrations may occur more frequently than is generally appreciated, and they affect the visual outcomes following cataract surgery. Small-aperture optics provide a solution for a large category of patients who are otherwise not well served by complex IOLs.
Diffractive multifocal IOL linked with progressive decline in vision in aging patients
January 27th 2022According to investigators, patients implanted with diffractive multifocal IOLs had notable declines in the corrected distance visual acuity, distance corrected near VA, and near area of focus with aging
Dry eye disease causes imbalance of neuropeptides, neurotrophins in cornea, trigeminal ganglion
December 30th 2021Impairment of corneal sensory innervation causes reduction of both protective reflexes and trophic neuromodulators that are essential for the vitality, metabolism, and wound healing of the ocular surface.
Though rare, ocular surface tumours often prove deadly
November 13th 2021In a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, Nathan Hall pointed out that an epidemiologic analysis of malignant ocular surface tumours found significant differences in geographic prevalence rates in the United States.
Mitomycin C associated with increase in corneal haze after corneal crosslinking
November 12th 2021Dr Shady Awwad in a presentation at the American Academy of Ophthalmology’s 2021 annual meeting in New Orleans, pointed out that the application of mitomycin C after corneal crosslinking does not prevent development of corneal haze after the procedure and instead contributes to development of more corneal haze.